Tag:

Parkinson's disease

Latest Headlines

Latest Headlines

Roche rolls out smartphones for continuous monitoring of participants in Parkinson's trial

Roche is using smartphones to gather data on participants in a Parkinson's disease clinical trial between site visits. The devices will enable both active and passive data collection, with patients being asked to complete daily tests and smartphone sensors gathering information as they go about their lives.

Meta-analysis: Avandia's impact on Parkinson's should spur new research

A meta-analysis of data from more than 160,000 diabetics has offered some convincing data to support the theory that PPARγ activation by glitazones--either Avandia (GlaxoSmithKline's rosiglitazone) or pioglitazone--offers significant protection against Parkinson's disease. And the researchers who did the study say that their work should help accelerate work in the field.

Pharma Two B mulls IPO after posting PhIIb Parkinson's data

Pharma Two B has stepped up its hunt for financing after its Parkinson's disease combination drug came through a Phase IIb trial. The data have given Pharma Two B the confidence to start talking up a possible IPO or partnership deal as it moves toward gathering the cash needed for a pivotal study.

Team spotlights new evidence that Parkinson's starts in the gut

Following up on what's billed as the largest epidemiological study ever done on Parkinson's disease, a group of scientists at Aarhus University in Denmark say they have determined that the neurological ailment begins in the gut and then spreads through the body by way of the vagus nerve.

Acorda's inhaled levodopa shows promise in Phase II trials

Acorda Therapeutics moved a step closer to collecting the payoff from its $525 million acquisition of Civitas, maker of an inhaled levodopa, in the scramble to deliver an improved formulation of the standard Parkinson's med. The conventional oral formulation suffers from unpredictable absorption in the bloodstream and a wearing-off effect after about 5 years.

FDA approves St. Jude's neurostimulator for Parkinson's, setting up rivalry with Medtronic

St. Jude Medical just received the FDA's coveted PMA approval for its Brio Neurostimulator System to treat the symptoms of Parkinson's and essential tremor. Brio joins Medtronic's Activa as the second deep-brain stimulation device on the market for those conditions.

Aussie startup gets $11.5M to market FDA-cleared, wearable Parkinson's disease tracker

Melbourne, Australia-based Global Kinetics expects that its Personal KinetiGraph can offer a better way for physicians to monitor the progression of Parkinson's disease and other movement disorders in patients and to see how the disease symptoms respond to specific treatments. The device provides an objective, continuous quantification of movement disorder symptoms.

Neuroderm stock up as FDA lifts hold on its subcutaneously delivered Parkinson's candidate

The FDA lifted the clinical hold on Neuroderm's subcutaneously delivered Parkinson's candidates, paving the way for more studies of the liquid formulations of levodopa and carbidopa in the second half of this year. In response to the Friday morning news, the company's stock ended the day up more than 10%.

UNC researchers hijack natural 'bubbles' to transport Parkinson's med

Getting drugs into the brain is one of the biggest challenges in medical research. Now a group of investigators at the University of North Carolina in Chapel Hill say they found an ideal method, hijacking tiny "bubbles" produced by cells and turning them into a delivery vehicle for a potent Parkinson's medication.

UNC scientists bypass blood-brain barrier with exosomes to treat Parkinson's

Exosomes are the small fat and protein bubbles that cells create to manage waste and transport materials. Naturally, then, the vesicles are ideal for use in drug delivery, and researchers are using exosomes to deliver antioxidants to the brain--bypassing the challenging blood-brain barrier--to treat Parkinson's disease.